this invention provides for advantageous combination therapies for solid tumors and leukemias , macular degeneration or obesity using methods which employ administration of a nsaid agent ( preferably a cox1 - 2 inhibitor ), a cytotoxic agent , an ester of benzoic acid ( preferably benzyl benzoate ), redox quinone , preferably vitamin k 3 and optionally , a bisphosphonate agent and / or mmp inhibitor and / or inhibitors of pro - angiogenic growth factors . the combination of the present invention results in a surprising reduction in tumor size . the pharmaceutical combination or each agent individually can be administered by any means known in the art . such modes include oral , rectal , nasal , topical ( including buccal and sublingual ), or parenteral ( including subcutaneous , intramuscular , intravenous , and intradermal ) administration , including sustained release formulations . for ease to the patient oral administration is preferred . however , typically oral administration requires a higher dose than an intravenous administration . thus , administration route will depend upon the situation : the skilled artisan must determine which form of administration is best in a particular case , balancing dose needed versus the number of times per month administration is necessary . in administering the compounds one can use the normal dose of each compound individually . however , with regard to the cytotoxic agent , in order to reduce side effects , preferably one uses a lower level than used when given as a single cytotoxic agent — typically 75 % or less of the individual amount , more preferably 50 % or less , still more preferably 40 % or less . conversely , with regard to the nsaid , mmp inhibitor , the bisphosphonate agent , redox quinone and the ester of benzoic acid , a dose equal to or higher than the recommended dose for their corresponding conventional indications is used . preferably , one uses a higher dose — typically 25 % or more than the highest recommended dose , more preferably 50 % or more , still more preferably 100 % or more . the first component of the combination therapy described is an anti - inflammatory agent . non - steroidal anti - inflammatory drugs , known as the nsaids , are among the most frequently prescribed agents and are typically used to treat diseases resulting from undesirable immune reactions . the biochemical effects of nsaids are widespread and diverse , including profound effects on cox1 and / or cox2 . their anti - inflammatory effect is mediated by an inhibition of prostaglandin production and decreased accumulation of macrophages and leukocytes at sites of inflammation . the invention can utilize a variety of nsaids . because this group of agents is so vast , only one example of each class of nsaids is detailed here . possible nsaids for the composition of the invention include but are not limited to salicylic acid derivatives ( such as aspirin , bristol - meyers squibb ), heteroaryl acetic acids ( such as diclofenac , novartis ), para - aminophenol derivatives ( such as acetaminophen , mcneil consumer ), indole and indene acetic acids ( such as indomethacin , merck ), aryl propionic acids ( such as ibuprofen , mylan ), anthranilic acids ( such as mefenamic acid , parke - davis ), enolic acids ( such as piroxicam , teva ), and alkones ( such as nabumetone , smithkline beecham ). a preferred nsaid is a cox2 inhibitor such as celecoxib (= celebrex , merck ), rofecoxib (= vioxx , pfizer / searle ), valdecoxcib , etoricoxib and cox - 189 . a most preferred nsaid is a cox 1 - 2 inhibitor such as diclofenac , ( norvatis ) or indomethacin ( merk ). the nsaid may be administered in any manner found appropriate by a clinician , such as those described in the physicians &# 39 ; desk reference , 56 th ed . ( 2002 ) publisher edward r . barnhart , new jersey (“ pdr ”). for example , when the nsaid is a cox1 - 2 inhibitor such as diclofenac , the dosage is 0 . 1 - 100 mg / kg ; preferably 1 - 10 mg / kg . the second component of the combination therapy described is a cytotoxic agent . currently available cytotoxic drugs can be broadly divided by their mechanism of action into four groups : alkylating agents , anti - metabolites , antibiotics , and miscellaneous other activities . the choice of a particular cytotoxic agent to treat an individual with cancer is influenced by many factors , including the type of cancer , the age and general health of the patient , and issues of multidrug resistance . the composition of the invention can utilize a variety of cytotoxic agents , including but not limited to the following agents ( including possible sources ): the alkylating agents cyclophosphamide ( bristol - meyers squibb ), ifosfamide ( bristol - meyers squibb ), chlorambucil ( glaxo wellcome ), and carmustine ( bristol - meyers squibb ); the anti - metabolites cytarabine ( pharmacia & amp ; upjohn ), 6 - mercaptopurine ( glaxo wellcome ), 6 - thioguanine ( glaxo wellcome ), and methotrexate ( immunex ); the antibiotics doxorubicin ( pharmacia & amp ; upjohn ), daunorubicin ( nexstar ), and mitoxantrone ( immunex ); and miscellaneous agents such as vincristine ( lilly ), vinblastine ( lilly ), and paclitaxel ( bristol - meyers squibb ). preferred cytotoxic agents include cyclophosphamide , ifosfamide , cytarabine , 6 - mercaptopurine , 6 - thioguanine , doxorubicin , daunorubicin , mitoxantrone , and vincristine . the most preferred cytotoxic agent are cyclophosphamide and ifosfamide . the cytotoxic agent may be administered in any manner found appropriate by a clinician , such as those described for individual cytotoxic agents in the pdr . for example , when the cytotoxic agent in cyclophosphamide , the dose is preferably 0 . 1 - 50 mg / kg , most preferably 0 . 2 - 20 mg / kg . the third component of the combination therapy described is an aliphatic ( alkyl ) or aromatic ester of benzoic acid . examples of alkyl esters of benzoic acid , include substituted and non - substituted benzoate . examples of alkyl esters of substituted benzoate are ethyl 3 - hydroxybenzoate or n - butyl p - aminobenzoate ( these examples are just for illustration because of numerous possibilities ). an aromatic ester of benzoic acid means non - substitute aromatic esters , like benzyl benzoate or esters where either the aromatic alcohol and / or the aromatic acid ( the benzoate ) are substituted . benzyl benzoate ( cas # 120 - 51 - 4 ) is an example of such agent used as a vehicle in the formulation of a variety of drugs . benzyl benzoate is a preferred ester of benzoic acid . benzyl benzoate is available commercially from bf goodrich kalama , inc . ( kalama , wash .). the ester of benzoic acid may be administered in any manner found appropriate by a clinician such as those described known in the drug formulation art . for example , when the ester of benzoic acid is benzyl benzoate the dosage is preferably 0 . 2 - 200 mg / kg , most preferably 1 - 50 mg / kg . additionally , it is preferred that the benzyl benzoate not be administered as a pure solution but is diluted to make a suspension of up to 20 % ( v / v ) benzyl benzoate in aqueous solution , preferably a 2 %- 10 % suspension . the fourth component of the combination therapy described is redox quinine , preferably vitamin k 3 . the dosage is preferably 0 . 1 - 100 mg / kg , most preferably 0 . 5 - 20 mg / kg . the vitamin k 3 may be formulated with benzyl benzoate and administered as part of the combination therapy . the fifth component of the combination therapy described is an inhibitor of an mmp . examples of inhibitors of an mmp include 11 , 10 - phenanthroline ( o - phenanthroline ); batarnistat also known as bb - 94 , [ 4 -( n - hydroxyamino )- 2r - isobutyl - 3s -( thiopen ylthiomethyl )- succinyl ]- l - phenylalanine - n - methylamidecarboxy - alkylamino - based compounds such as n + 1 -( r )- carboxy ( 1 , 3 - dihydro - 2h - benz [ f ] isoindol yl ) propyl ]- n ′, n ′- dimethyl - l - leucinamide , trifluoroacetate ( j . med chem . 36 : 4030 - 4039 , 1993 ); marimastat ( bb - 2516 ); n - chlorotaurine ; eicosapentaenoic acid ; matlystatin - b ; actinonin ( 3 -[[ 1 -[[ 2 -( hydroxymethyl )- 1 - pyrolidinyl ] carbamoyl ]- octanohydroxamic acid ); n - phosphonalkyl dipeptides such as n -[ n -(( r )- 1 - phosphonopropyl -( s )- leucyl ]-( s )- phenylalanine - n - methylamide ( j . med . chem . 37 : 158 - 169 , 1994 ); peptidylhydroxamic acids such as pnh2 - bz - gly - pro - d - leu - d - ala - nhoh ( biophys . biochem . res . comm . 199 : 1442 - 1446 , 1994 ); ro 7467 , also known as 2 + 5 - bromo - 2 , 3 - dihydro hydroxy - 1 , 3 - dioxo - 1hbenz [ de ] isoquinolin yl ) methyl ]( hydroxy )-[ phosphinyl ]- n -( 2 - oxo azacyclotridecanyl ) methylvaleramide ; ct 1 166 , also known as n i f n -[ 2 -( morpholinosulphonylamino )- ethyl ]- 3 - cyclohexyl - 1 5 2 -( s )- propanamidyl 1 - n - 4 - hydroxy ( r )-[ 3 -( 4 - methylphenyl ) propyl ]- succinamide ( biochem . j . 308 : 167 - 175 , 1995 ); bromocyclic - adenosine monophosphate ; protocatechuic aldehyde ( 3 , 4 - dihydroxybenzaldehyde ); estramustine ( estradiol bis ( 2 - chloroethyl ) carbamate ). yet another example of mmp inhibitors are doxycycline or cmt - 8 ( j . periodontol . 73 : 726 - 734 , 2002 ). a particular inhibitor may inhibit more than one mmp . the inhibitor may inhibit , for example , mmp - 1 ( interstitial collagenase ), mmp - 2 ( 72 kdcollagenase ), mw - 3 stromelysin ), mmp - 4 ( telopeptidase ), mmp - 5 ( collagenendopeptidase ), nimp - 6 ( acid metalloproteinase ), mmp - 7 ( uterinemetalloproteinase ), mmp - 8 ( neutrophil collagenase ), and / or mmp - 9 ( 92 kdcollagenase ). a direct and / or indirect inhibitor of an mmp may be used . an optional component of the combination therapy described is a bisphosphonate . the bisphosphonates of the present invention correspond to the chemical formula : wherein a and x are independently selected from the group consisting of h , oh , halogen , nh 2 , sh , phenyl , c1 - c30 alkyl , c1 - c30 substituted alkyl , c1 - c10 alkyl or dialkyl substituted nh 2 , c1 - c10 alkoxy , c1 - c10 alkyl or phenyl substituted thio , c1 - c10 alkyl substituted phenyl , pyridyl , furanyl , pyrrolidinyl , imidazonyl , and benzyl . in the foregoing chemical formula , the alkyl groups can be straight , branched , or cyclic , provided sufficient atoms are selected for the chemical formula . the c1 - c30 substituted alkyl can include a wide variety of substituents , nonlimiting examples which include those selected from the group consisting of phenyl , pyridyl , furanyl , pyrrolidinyl , imidazonyl , nh 2 , c1 - c10 alkyl or dialkyl substituted nh 2 , oh , sh , and c1 - c10 alkoxy . in the foregoing chemical formula , a can include x and x can include a such that the two moieties can form part of the same cyclic structure . the foregoing chemical formula is also intended to encompass complex carbocyclic , aromatic and hetero atom structures for the a and / or x substituents , nonlimiting examples of which include naphthyl , quinolyl , isoquinolyl , adamantyl , and chlorophenylthio . preferred structures are those in which a is selected from the group consisting of h , oh , and halogen , and x is selected from the group consisting of c1 - c30 alkyl , c1 - c30 substituted alkyl , halogen , and c1 - c10 alkyl or phenyl substituted thio . more preferred structures are those in which a is selected from the group consisting of h , oh , and cl , and x is selected from the group consisting of c1 - c30 alkyl , c1 - c30 substituted alkyl , cl , and chlorophenylthio . most preferred is when a is oh and x is a 3 - aminopropyl moiety , so that the resulting compound is a 4 - amino - 1 ,- hydroxybutylidene - 1 , 1 - bisphosphonate , i . e . alendronate . pharmaceutically acceptable salts and derivatives of the bisphosphonates are also useful herein . nonlimiting examples of salts include those selected from the group consisting alkali metal , alkaline metal , ammonium , and mono -, di , tri -, or tetra - c1 - c30 - alkyl - substituted ammonium . preferred salts are those selected from the group consisting of sodium , potassium , calcium , magnesium , and ammonium salts . nonlimiting examples of derivatives include those selected from the group consisting of esters , hydrates , and amides . “ pharmaceutically acceptable ” as used herein means that the salts and derivatives of the bisphosphonates have the same general pharmacological properties as the free acid form from which they are derived and are acceptable from a toxicity viewpoint . it should be noted that the terms “ bisphosphonate ” and “ bisphosphonates ”, as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates , biphosphonic acids , and diphosphonic acids , as well as salts and derivatives of these materials . alendronate ( also known as alendronate sodium or monosodium trihydrate ), 4 - amino - 1 - hydroxybutylidene - 1 , 1 - bisphosphonic acid monosodium trihydrate . alendronic acid and alendronate are described in u . s . pat . no . 4 , 922 , 007 , to kieczykowski et al ., issued may 1 , 1990 , and u . s . pat . no . 5 , 019 , 651 , to kieczykowski , issued may 28 , 1991 , both of which are incorporated by reference herein in their entirety . cycloheptylaminomethylene - 1 , 1 - bisphosphonic acid , ym 175 , yamanouchi ( cimadronate ), as described in u . s . pat . no . 4 , 970 , 335 , to isomura et al ., issued nov . 13 , 1990 , which is incorporated by reference herein in its entirety . 1 , 1 - dichloromethylene - 1 , 1 - diphosphonic acid ( clodronic acid ), and the disodium salt ( clodronate , procter and gamble ), are described in belgium patent 672 , 205 ( 1966 ) and j . org . chem 32 , 4111 ( 1967 ), both of which are incorporated by reference herein in their entirety . 1 - hydroxy - 3 -( n - methyl - n - pentylamino ) propylidene - 1 , 1 - bisphosphonic acid , also known as bm - 210955 , boehringer - mannheim ( ibandronate ), is described in u . s . pat . no . 4 , 927 , 814 , issued may 22 , 1990 , which is incorporated by reference herein in its entirety . [ 2 -( 2 - pyridinyl ) ethylidene ]- 1 , 1 - bisphosphonic acid ( piridronate ) is described in u . s . pat . no . 4 , 761 , 406 , which is incorporated by reference in its entirety . ( 4 - chlorophenyl ) thiomethane - 1 , 1 - disphosphonic acid ( tiludronate ) as described in u . s . pat . no . 4 , 876 , 248 , to breliere et al ., oct . 24 , 1989 , which is incorporated by reference herein in its entirety . the bisphosphonate may be administered in a dosage and manner found appropriate by a clinician such as those described for individual biphosphonates in the pdr . for example , when the bisphosphonate is pamidronate , the dose is 0 . 10 - 10 mg / kg , preferably 0 . 5 - 5 mg / kg . in a further optional embodiment , inhibitors of pro - angiogenic growth factors are included in the combination . such inhibitors can prevent the growth factor binding or inhibit its intracellular signaling . in another embodiment , a steroidal anti - inflammatory agent is included in the combination . in an optional embodiment , the composition of the invention can utilize a variety of steroidal anti - inflammatory agents , including but not limited to the following agents ( including possible sources ): dexamethasone ( merck ), betamethasone ( schering ), triamcinolone ( fujisawa ), 6a - methylprednisolone ( duramed ), prednisolone ( merck ), prednisone ( roxane ), hydrocortisone ( merck ), cortisone ( merck ), and fludrocortisone ( apothecon ). preferred agents are dexamethasone , betamethasone , triamcinolone , 6a - methylprednisolone , and prednisolone . dexamethasone and prednisone are the most preferred steroidal anti - inflammatory agents . the steroidal anti - inflammatory agent ( said ) may be administered in any manner found appropriate by a clinician in generally accepted efficacious dose ranges such as those described for individual saids in the pdr . as with the use of other chemotherapeutic drugs , the individual patient will be monitored in a manner deemed appropriate by the treating physician . typically , no additional drug treatments will occur until , for example , the patient &# 39 ; s neutrophil count is at least 1500 cells / mm 3 . dosages can also be reduced if severe neutropenia or severe peripheral neuropathy occurs , or if a grade 2 or higher level of mucositis is observed , using the common toxicity criteria of the national cancer institute . the pharmaceutical compositions of this invention which are found in combination may be in the dosage form of solid , semi - solid , or liquid such as , e . g . suspension , aerosols , or the like . preferably the compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts . the compositions may also include , depending on the formulation desired , pharmaceutically - acceptable , nontoxic carriers or diluents , which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration . compositions may be provided as sustained release or timed release formulations . the carrier or diluent may include any sustained release material known in the art , such as glyceryl monostrearate or glyceryl distearate , alone or mixed with a wax . microencapsulation may also be used . the timed release formulation can provide a combination of immediate and pulsed release throughout the day . the diluent is selected so as not to affect the biological activity of the combination . examples of such diluents are distilled water , physiological saline , ringer &# 39 ; s solution , dextrose solution , and hank &# 39 ; s solution . in addition , the pharmaceutical composition of formulation may also include other carriers , adjuvants , emulsifiers such as poloxamers , or nontoxic , nontherapeutic , nonimmunogenic stabilizers and the like . effective amounts of such diluent or carrier will be those amounts which are effective to obtain a pharmaceutically acceptable formulation in terms of solubility of components , or biological activity , and the like . in therapeutic applications , the dosages and administration schedule of the agents used in accordance with the invention vary depending on the agent , the age , weight , and clinical condition of the recipient patient , and the experience and judgment of the clinician or practitioner administering the therapy , among other factors affecting the selected dosage . generally , the dose and administration scheduled should be sufficient to result in slowing , and preferably regressing , the growth of the tumor ( s ) and also preferably causing complete regression of the cancer . in some cases , regression can be monitored by a decrease in blood levels of tumor specific markers . an effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer . regression of a tumor in a patient is typically measured with reference to the diameter of a tumor . decrease in the diameter of a tumor indicates regression . regression is also indicated by failure of tumors to reoccur after treatment has stopped . the agents in combination , or separately , are delivered at periodic intervals that can range from several times a day to once per month . as noted above , the agents are administered until the desired therapeutic outcome has been obtained . additionally , in order to avoid side - effects not all components of the combination need to be delivered at each administration . for example , if the combination is administered twice a week the biphosphonates can be administered only once a week ( every second treatment ). this invention further includes pharmaceutical combinations comprising a non - steroidal anti - inflammatory drug , a cytotoxic agent , an ester of benzoic acid , redox quinone and optionally , a bisphosphonate and / or mmp inhibitor and / or inhibitors of pro - angiogenic factors as provided above and kits for the treatment of cancer patients comprising a vial of the anti - inflammatory agent , a vial of the cytotoxic agent and a vial of the ester of benzoic acid , at the doses provided above . preferably , the kits also include a vial of redox quinone . most preferably , the kit contains instructions describing their use in combination . in addition , the full treatment kit includes a formulation of at least two of the agents and / or a formulation of a cytotoxic agent alone and / or a formulation of benzyl benzoate and vitamin k 3 . it is understood that the foregoing detailed description and the following examples are illustrative only and are not to be taken as limitations upon the scope of the invention . various changes and modifications to the disclosed embodiments , which will be apparent to those skilled in the art , may be made without departing from the spirit and scope of the present invention . further , all patents , patent applications , and publications cited herein are incorporated herein by reference . breast cancer is a highly lethal disease . to test the efficacy of rofecoxib , benzyl benzoate , cyclophosphamide , and pamidronate alone and in combination , a mouse breast cancer cell line , emt6 , that was originally isolated from a spontaneous tumor in a balb / c mouse was used ( twentyman p r and watson j v , br . j . cancer 35 : 120 ( 1977 )). this line was further selected for a drug resistant variant , emt6 / ctx , that was used in this study ( teicher b a et al . cancer chemother . pharmacol . 37 : 601 ( 1996 )). an emt6 / ctx cell suspension was freshly prepared in dmem medium + 10 % fcs , following trypsinization of cell grown in tissue culture . anesthesia is performed by injecting 0 . 08 ml per mouse of ketamine 30 mg / ml + 0 . 07 % chanazine in pbs . subcutaneous inoculation of 3 × 10 5 cells at the shaved back of anesthetized c57blxbalb / c f1 7 - 8 weeks old male mice results in palpable tumors within 4 days , and animals succumb to the tumor with around 4 weeks . thus , this is a highly aggressive tumor growth model . rofecoxib ( vioxx , a merck & amp ; co . inc . product ), as an oral suspension . diclofenac , water - soluble vitamin k 3 ( menadione sodium bisulfite ) and benzyl benzoate , purchased from sigma - aldrich ( st . louise , mich . ), were formulated into solution in double - distilled water plus 2 % tween 20 ( j . t . baker , nj ). cyclophosphamide , purchased from bristol - meyers squibb ( princeton , n . j . ), was formulated into solution in double - distilled water plus 2 % tween 20 . pamidronate ( pamidronic acid ) was dissolved in 2m hepes . the following doses were used for treatment in all three experiments : rofecoxib 10 mg / kg , pamidronate 10 mg / kg , diclofenac 30 or 60 mg / kg , menadione sodium bisulfite 20 or 50 mg / kg , cyclophosphamide ( ctx ) 50 , 60 or 100 mg / kg and benzyl benzoate 80 or 550 mg / kg . vehicle : 2 % tween 20 in double distilled water . the preparations were made in a concentration that will require an i . p . injection of 0 . 1 ml per 20 gr body weight to achieve the above doses . group 1 . control vehicle ; group 2 . benzyl benzoate 550 mg / kg ( a ) and pamidronate 10 mg / kg ( b ) group 3 . b and rofecoxib 10 mg / kg ( c ) group 4 . a and c all treatments were started 5 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated twice a week for a period of 3 weeks . tumor dimensions were measured twice a week . tumor volume was calculated according to conventional methods ( volume = a 2 × b × 0 . 52 where a represents the tumor width and b is its length ) and the data are represented as changes in tumor volume with time . toxicity was evaluated by qualitative observation of the general appearance and behavior of the mice , by measuring their body weight during various intervals during the course of the treatments and by obtaining mortality data . the results of this experiment are set forth in fig1 . as can be seen , none of the combination of two agents has a significant effect on the tumor volume . the tumor model , drug formulation and tumor volume measurements were identical to experiment 1 . again , 6 mice were used for each group . this experiment tested the effect of the drug combination of a + b + c . the treatment started 5 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated twice a week for a period of 3 weeks . the results of this experiment are set forth in fig2 . as can be seen , the combination abc dramatically reduced tumor growth . mice exhibited less than 10 % weight loss and no toxicity was observed . the tumor model , drug formulation and tumor volume measurements were identical to experiment 1 . seven mice were used for each group . this experiment tested the effect of cyclophosphamide by itself and with the drug combination of abc . group 1 . control vehicle group 2 . cyclophosphamide 50 mg / kg ( ctx 50 ) group 3 . abc group 4 . abc + ctx50 the treatment started 3 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated twice a week for a period of 4 weeks . the results are presented in fig3 and demonstrated the superiority of the x4 combination protocol . while ctx 50 and abc each by itself has a moderate effect on tumor growth , the x4 combination of abc + ctx 50 yielded a synergistic effect . the tumor model , drug formulation and tumor volume measurements were identical to experiment 1 . seven mice were used for each group . this experiment tested the effect of cyclophosphamide by itself , with the drug combination of abc and the effect of administrating small doses of a ( 1 / 6 ) 6 times a week . group 1 . control vehicle group 2 . cyclophosphamide 50 mg / kg ( ctx 50 ) group 3 . ctx 50 + abc group 4 . ( ctx 50 + bc )× 2 per week + 1 / 6a × 6 per week (= a all week ) the treatment started 4 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated twice a week ( group 4 was treated 6 times a week ) for a period of 4 weeks . the results are presented in fig4 and demonstrated the superiority of spreading the dose of a throughout the week . the tumor model , drug formulation and tumor volume measurements were identical to experiment 1 . seven mice were used for each group . this experiment tested the effect of changing the treatment regime : once a week vs . twice and injecting bc together with ctx on the same day vs . on different days of the week group 1 . control vehicle group 2 . ( bc + ctx 50 )× 2 per week ; a all week ( sun .- fri .) group 3 . ( bc + ctx 100 ) once a week ; a all week ( sun .- fri .) group 4 . bc wed . ; ctx 100 sun . ; a all week ( sun .- fri .) the treatment started 4 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated once , twice or 6 times a week for a period of 4 weeks , according to the above protocol . the results are presented in fig5 and demonstrated the possible advantage of injecting bc and ctx on different days of the weekly cycle . the tumor model , drug formulation and tumor volume measurements were identical to experiment 1 . seven mice were used for each group . this experiment tested the replacement of b by doubling the dose of c ( 2c no b ) and the usage of diclofenac 25 mg / kg ( d ) with b or twice its dose ( 2d ) without b , as the nsaid of choice . group 1 . control vehicle group 2 . bc wed . ; ctx 100 sun . ; a all week group 3 . 2c wed . ; ctx 100 sun . ; a all week group 4 . bd wed . ; ctx 100 sun . ; a all week group 5 . 2d wed . ; ctx 100 sun . ; a all week the treatment started 3 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated 6 times a week for a period of 4 weeks . the results are presented in fig6 and demonstrated that larger doses (× 2 ) of nsaids can be used to substitute the need of b . fig6 also demonstrated the superiority of d ( 25 and 50 mg / kg ) over c ( 5 and 10 mg / kg , respectively ). the tumor model , drug formulation and tumor volume measurements were identical to experiment 1 . seven mice were used for each group . this experiment tested the effect of changing the time intervals between administration of ctx and d ( 1 , 3 or 5 days apart ) and the “ spreading ” of the ctx dose throughout the week ( 20 mg / kg 6 times a week ). group 1 . control vehicle group 2 . ctx 100 sun . ; d50 wed . ; a all week group 3 . ctx 100 sun . ; d50 mon . ; a all week group 4 . ctx 100 sun . ; d50 fri . ; a all week group 5 . ctx20 all week ( sun - fri ); d50 wed . ; a all week the treatment started 5 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated 6 times a week for a period of 4 weeks . the results are presented in fig7 and demonstrated that treatment with ctx 100 once a week is preferred over equal small doses throughout the week and that the interval between administration of ctx and d should be at most 1 day . the tumor model , drug formulation and tumor volume measurements were identical to experiment 1 . seven mice were used for each group . this experiment tested the effect of the addition of vitamin k 3 ( vk ) at doses of 20 mg / kg 6 times a week or 50 mg / kg twice a week , to the formulation . the days of the week are abbreviated as follows : sun . ( s ), mon . ( m ), tues . ( t ), wed . ( w ), thu . ( h ), and fri ( f ). the treatment started 4 days after cell inoculation . treatment comprised an intraperitoneal injection of 0 . 1 ml per 20 gr body weight of the formulation . mice were treated 6 times a week for a period of 4 weeks . the results are presented in fig8 and demonstrated that ( a ) the addition of vk improve the efficacy of the treatment ; ( b ) the administration of vk at lower doses throughout the week ( every day ) is preferable . the treatment was a combination of four drugs supplied for a specific dosing schedule . the drugs included cyclophosphamide ( ctx ), diclofenac ( voltaren ), vitamin k3 ( menadione ) and benzyl benzoate that was provided as part of a suspension suitable for oral administration . all these drugs were formulated in an oral suspension composed of 2 % lutrol ® f68 and 2 % solutol ® hs - 15 ( suspending agents ) and 1 . 15 % benzyl benzoate , in water . the drug combination was prepared under sterile , gmp conditions in the sheba medical center pharmacy . the drug combination was supplied in 25 ml , 37 . 5 , and 50 ml doses . the amounts of the drugs supplied were as follows : cyclophosphamide 200 mg ( approximately 60 mg / kg / week )* diclofenac 100 mg ( approximately 30 mg / kg / week )* vitamin k3 70 mg ( approximately 7 mg / kg / week )* 25 ml dose for use on the rest of the week ( 5 days ): cyclophosphamide 300 mg ( approximately 90 mg / kg / week )* diclofenac 150 mg ( approximately 45 mg / kg / week )* vitamin k3 105 mg ( approximately 10 . 5 mg / kg / week )* 37 . 5 ml dose for use on the rest of the week ( 5 days ): cyclophosphamide 400 mg ( approximately 120 mg / kg / week )* diclofenac 200 mg ( approximately 60 mg / kg / week )* vitamin k3 140 mg ( approximately 14 mg / kg / week )* * assuming an average body weight of 70 kg 50 ml dose for use on the rest of the week ( 5 days ): the drug combination was supplied in numbered tubes ( 1 - 7 ), one for each day of the week . the tubes were shaken well before use , to insure homogenization of the suspension . tubes with blue caps contain the cytotoxic agent and were administered twice weekly ( days # 1 and # 4 ). gloves were worn when using these tubes and they were handled with extra care . tubes with red caps were taken on the other five days of the week ( 2 , 3 , 5 , 6 , and 7 ). all tubes were stored in a freezer (− 20 ° c .) until distributed to patients . the patients kept the tubes stored in a refrigerator , protected from light and out of the reach of children . the suspension was taken orally in the evening during or after dinner . the drug was supplied so that the patient received vitamin k3 daily . cyclophosphamide and diclofenac were administered twice weekly in combination with vitamin k3 . the initial dose was 25 ml administered daily for two weeks . if no significant toxicity occurred , the next dose of 37 . 5 ml was administered for two weeks . if the patient tolerated this dose , treatment was continued with administration of 50 ml of drug combination for eight weeks . no major side effects were observed during 1 to 3 months treatment of 30 patients ( except for a manageable bitter taste ). early signs of stable disease or regression in 7 out of 12 patients were evaluated at 12 wks ( imaging ). 2 colon cancer patients were stable after 20 wks on combinations ( vs . a steady progression beforehand despite treatment ). in one patient an mri taken before the initiation of the drug - combination treatment showed a tumor mass that compressed the right urethra and interfered with urine flow . an mri of the same section kidney was taken two months after the initiation of the drug - combination treatment showed a significant shrinkage of the tumor and an improvement of the kidney condition . although the foregoing invention has been described in some detail by way of illustration and example for the purposes of clarity of understanding , one skilled in the art will easily ascertain that certain changes and modifications may be practiced without departing from the spirit and scope of the appended claims .
the present invention relates to the surprising discovery that the combination of several agents , each well known for its established role in treating cancer , inflammation , hemostasis , bone resorption or serving as a solubilizing vehicle , results in a synergistic anti - cancer composition . furthermore , the combination of at least three agents allows the cytotoxic agent , such as cyclophosphamide , to be used at a lower dosage than when administered alone . one predicted consequence of this treatment , therefore , is a highly desirable reduction in toxic side effects due to the cytotoxic agent .